삼성서울병원

Ko En

Hematology-Oncology Im, Young Hyuck M.D

Expertise
Breast cancer, medical treatment, clinical & translational research for breast cancer
Treament Schedule 02 月
DATE
SAT
01
SUN
02
MON
03
TUE
04
WEB
05
THU
06
FRI
07
SAT
08
SUN
09
MON
10
TUE
11
WEB
12
THU
13
FRI
14
SAT
15
SUN
16
MON
17
TUE
18
WEB
19
THU
20
FRI
21
SAT
22
SUN
23
MON
24
TUE
25
WEB
26
THU
27
FRI
28
AM
PM
Treament Schedule 03 月
DATE
SAT
01
SUN
02
MON
03
TUE
04
WEB
05
THU
06
FRI
07
SAT
08
SUN
09
MON
10
TUE
11
WEB
12
THU
13
FRI
14
SAT
15
SUN
16
MON
17
TUE
18
WEB
19
THU
20
FRI
21
SAT
22
SUN
23
MON
24
TUE
25
WEB
26
THU
27
FRI
28
SAT
29
SUN
30
MON
31
AM
PM

Medical Education

1994~1996 Ph.D. in Medicine Seoul National University, Korea
1991~1993 Master in Medicine Seoul National University, Korea
1980~1984 Bachelor in Medicine College of Medicine, Seoul National University, Korea

Post-Graduate Training

Fellowship   1991~1992 Division of Hematology/Oncology, Seoul National University Hospital, Korea
Residency   1989~1991 Department of Internal Medicine, Seoul National University Hospital, Korea
Internship   1987~1988 Seoul National University Hospital, Korea

Professional Appointments

2010~Present Professor Division of Hematology/Oncology, Sungkyunkwan University School of Medicine
2020~2022 Executive Vice President Medical Affairs, Sungkyunkwan University School of Medicine
2015~2020 Executive Vice President Research Institute for Future Medicine, Samsung Medical Center
2011~2014 Director Clinical Research Institute, Research Institute for Future Medicine, Samsung Medical Center
2011~2013 Chair Division of Hematology/Oncology, Samsung Medical Center
2011~2013 Associate Director Samsung Comprehensive Cancer Center, Samsung Medical Center
2010~2011 Director Research planning & strategy, Office of Biomedical Research, Samsung Medical Center
2005~2009 Director Breast Cancer Center, Samsung Medical Center
2004~2010 Associate professor Division of Hematology/Oncology, Sungkyunkwan University School of Medicine
2000~2004 Assisstant professor Division of Hematology/Oncology, Sungkyunkwan University School of Medicine
1997~2000 Research Fellow National Cancer Institute, National Institute of Health(NIH), USA
1992~1997 Section Chief Section of Hematology/Oncology II, Korea Cancer Center Hospital

Professional Memberships

2015~Present Member European Society of Medical Oncology(ESMO)
2016~Present Member American Association for Cancer Research(AACR)
1996~Present Member American Society of Clinical Oncology(ASCO)
2006~Present Member Korean Society of Medical Oncology(KSMO)
2002~Present Member Korean Cancer Association(KCA)
2001~Present Member Korea Cancer Study Group(KCSG)
2016~2018 Chair Board of Directors, Korean Society of Medical Oncology(KSMO)
2010~2014 Chair Education Committee, Korean Association for Clinical Oncology(KACO)
2007~2011 Chair Breast Cancer Committee, Korea Cancer Study Group(KCSG)

Selected Publications

  • J CLIN ONCOL 2024 10.1200/JCO.23.02374 Scalp Cooling in Preventing Persistent Chemotherapy-Induced Alopecia: A Randomized Controlled Trial Kang, D; Cho, J; Zhao, D; Kim, J; Kim, N; Kim, H; Kim, S; Kim, JY; Park, YH; Im, YH; Guallar, E; Ahn, JS
    View PubMed
  • NPJ BREAST CANCER 2024 10.1038/s41523-024-00669-9 Prognostic value of structural variants in early breast cancer patients Kim, JY; Park, K; Park, WY; Ahn, JS; Im, YH; Lee, JE; Kim, SW; Nam, SJ; Yu, J; Park, YH
    View PubMed
  • CLIN CANCER RES 2024 10.1158/1078-0432.CCR-23-2513 Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer Tan, TJ; Sammons, S; Im, YH; She, LL; Mundy, K; Bigelow, R; Traina, TA; Anders, C; Yeong, J; Renzulli, E; Kim, SB; Dent, R
    View PubMed
  • CLIN CANCER RES 2024 10.1158/1078-0432.CCR-23-0133 A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer Cescon, DW; Hilton, J; Murilo, SM; Layman, RM; Pluard, T; Yeo, B; Park, IH; Provencher, L; Kim, SB; Im, YH; Wyce, A; Krishnatry, AS; Hicks, K; Zhang, Q; Barbash, O; Khaled, A; Horner, T; Dhar, A; Oliveira, M; Sparano, JA
    View PubMed
  • BREAST 2023 10.1016/j.breast.2023.103594 Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/ pertuzumab for HER2-positive breast cancer Kim, N; Kim, JY; Park, W; Cho, WK; Kim, TG; Im, YH; Ahn, JS; Lee, JE; Nam, SJ; Kim, SW; Yu, J; Chae, BJ; Lee, SK; Ryu, JM; Park, YH; Kim, H
    View PubMed
  • INT J MOL SCI 2023 10.3390/ijms242115576 A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Jung, HH; Kim, JY; Cho, EY; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • RADIAT ONCOL 2023 10.1186/s13014-023-02357-7 Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach Kim, N; Kim, H; Park, W; Cho, WK; Kim, TG; Im, YH; Ahn, JS; Park, YH; Kim, JY
    View PubMed
  • CANCERS 2023 10.3390/cancers15194720 Comprehensive Clinical Characterization of Decade-Long Survivors of Metastatic Breast Cancer Shin, J; Kim, JY; Oh, JM; Lee, JE; Kim, SW; Nam, SJ; Park, W; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • EXP MOL MED 2023 10.1038/s12276-023-01030-z Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer Kim, JY; Park, S; Cho, EY; Lee, JE; Jung, HH; Chae, BJ; Kim, SW; Nam, SJ; Cho, SY; Park, YH; Ahn, JS; Lee, S; Im, YH
    View PubMed
  • CANCERS 2023 10.3390/cancers15133431 Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Kim, JY; Shin, J; Ahn, JS; Park, YH; Im, YH
    View PubMed
  • CANCER MED-US 2023 10.1002/cam4.5953 TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors Kim, JY; Jung, J; Kim, KM; Lee, J; Im, YH
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.1360 A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03) Lee, DW; Keam, B; Lee, KS; Ahn, JH; Sohn, J; Ahn, JS; Lee, MH; Kim, JH; Lee, KE; Kim, HJ; Kim, SY; Park, YH; Ock, CY; Lee, KH; Han, SW; Kim, SB; Im, YH; Chung, HC; Oh, D; Im, SA
    View PubMed
  • J BREAST CANCER 2023 10.4048/jbc.2023.26.e17 Prognostic Impact of Elevation of Cancer Antigen 15-3 (CA15-3) in Patients With Early Breast Cancer With Normal Serum CA15-3 Level Ryu, JM; Kang, DB; Cho, JH; Lee, JE; Kim, SW; Nam, SJ; Lee, SK; Kim, YJ; Im, YH; Ahn, JS; Park, YH; Kim, JY; Lee, HYJ; Kang, MR; Yu, JH
    View PubMed
  • MOL ONCOL 2023 10.1002/1878-0261.13416 ER+, HER2-advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes Chen, JW; Jacot, W; Cortes, J; Krop, IE; Dent, S; Harbeck, N; De Laurentiis, M; Dieras, V; Im, YH; Stout, TJ; Schimmoller, F; Savage, HM; Hutchinson, KE; Wilson, TR
    View PubMed
  • FRONT ONCOL 2023 10.3389/fonc.2023.1146934 Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer Kim, JY; Kim, J; Cho, EY; Park, YH; Ahn, JS; Kim, KM; Im, YH
    View PubMed
  • BREAST CANCER-TOKYO 2023 10.1007/s12282-023-01436-7 Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1) Imoto, S; Wang, K; Bi, XW; Liu, GY; Im, YH; Im, SA; Sim, SH; Ueno, T; Futamura, M; Toi, M; Fujiwara, Y; Ahn, SG; Lee, JE; Park, YH; Takao, S; Oba, MS; Kitagawa, Y; Nishiyama, M
    View PubMed
  • ONCOLOGIST 2022 10.1093/oncolo/oyac234 Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1 Toi, M; Boyle, F; Im, YH; Reinisch, M; Molthrop, D; Jiang, ZF; Wei, R; Sapunar, F; Grimes, BR; Nabinger, SC; Johnston, SRD
    View PubMed
  • CANCER RES TREAT 2022 10.4143/crt.2021.901 Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/ Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience Kim, JY; Nam, SJ; Lee, JE; Yu, J; Chae, BJ; Lee, SK; Ryu, JM; Ahn, JS; Im, YH; Kim, SW; Park, YH
    View PubMed
  • CANCERS 2022 10.3390/cancers14194839 Long-Term Breast Cancer Outcomes of Pregnancy-Associated Breast Cancer (PABC) in a Prospective Cohort Jo, H; Park, S; Kim, HR; Kim, H; Hong, J; Lee, JE; Yu, J; Chae, BJ; Lee, SK; Ryu, JM; Oh, SY; Choi, SJ; Kim, JY; Ahn, JS; Im, YH; Nam, EM; Nam, SJ; Park, YH
    View PubMed
  • CANCER SCI 2022 10.1111/cas.15600 Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2 Toi, M; Huang, CS; Im, YH; Sohn, J; Zhang, W; Sakaguchi, S; Haddad, N; van Hal, G; Sledge , GW
    View PubMed
  • CANCER RES TREAT 2022 10.4143/crt.2021.1103 Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer Lee, YP; Lee, MS; Kim, H; Kim, JY; Ahn, JS; Im, YH; Park, YH
    View PubMed
  • J AM ACAD DERMATOL 2022 10.1016/j.jaad.2021.10.047 Efficacy of a tailored moisturizer for reducing chemotherapy-induced skin dryness in breast cancer patients: A randomized controlled clinical trial Kang, D; Kim, N; Im, YH; Park, YH; Kim, JY; Park, H; Kim, E; Zhao, D; Guallar, E; Ahn, JS; Cho, J
    View PubMed
  • FRONT ONCOL 2022 10.3389/fonc.2022.903372 Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy Kim, JY; Oh, JM; Lee, SK; Yu, J; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Kim, K; Im, YH
    View PubMed
  • ANN ONCOL 2022 10.1016/j.annonc.2022.03.006 Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study Rugo, HS; O'Shaughnessy, J; Boyle, F; Toi, M; Broom, R; Blancas, I; Gumus, M; Yamashita, T; Im, YH; Rastogi, P; Zagouri, F; Song, C; Campone, M; San Antonio, B; Shahir, A; Hulstijn, M; Brown, J; Zimmermann, A; Wei, R; Johnston, SRD; Reinisch, M; Tolaney, SM
    View PubMed
  • CLIN CANCER RES 2022 10.1158/1078-0432.CCR-21-3032 Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2(-) Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial Lu, YS; Im, SA; Colleoni, M; Franke, F; Bardia, A; Cardoso, F; Harbeck, N; Hurvitz, S; Chow, L; Sohn, J; Lee, KS; Campos-Gomez, S; Vazquez, RV; Jung, KH; Babu, KG; Wheatley-Price, P; De Laurentiis, M; Im, YH; Kuemmel, S; El-Saghir, N; O'Regan, R; Gasch, C; Solovieff, N; Wang, C; Wang, YY; Chakravartty, A; Ji, Y; Tripathy, D
    View PubMed
  • THER ADV MED ONCOL 2022 10.1177/17588359221081203 Correlation between work productivity loss and EORTC QLQ-C30 and-BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2-advanced breast cancer Tripathy, D; Curteis, T; Hurvitz, S; Yardley, D; Franke, F; Babu, KG; Wheatley-Price, P; Im, YH; Pencheva, R; Eddowes, LA; Dionne, PA; Chandiwana, D; Pathak, P; Lanoue, B; Harbeck, N
    View PubMed
  • J CLIN ONCOL 2022 10.1200/JCO.21.00896 Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study Krop, IE; Im, SA; Barrios, C; Bonnefoi, H; Gralow, J; Toi, M; Ellis, PA; Gianni, L; Swain, SM; Im, YH; De Laurentiis, M; Nowecki, Z; Huang, CS; Fehrenbacher, L; Ito, Y; Shah, J; Boulet, T; Liu, HY; Macharia, H; Trask, P; Song, CY; Winer, EP; Harbeck, N
    View PubMed
  • CANCER PREV RES 2021 10.1158/1940-6207.CAPR-20-0542 The Relationship Between Breast Density Change During Menopause and the Risk of Breast Cancer in Korean Women Kang, D; Kim, JY; Kim, JY; Mun, HS; Yoon, SJ; Lee, J; Han, G; Im, YH; Shin, SY; Lee, SK; Yu, JH; Lee, KH; Kim, M; Park, D; Choi, YH; Jeong, OS; Lee, JH; Jekal, SY; Choi, JS; Guallar, E; Chang, Y; Ryu, S; Cho, J; Kang, M
    View PubMed
  • PLOS ONE 2021 10.1371/journal.pone.0260681 Privacy-preserving breast cancer recurrence prediction based on homomorphic encryption and secure two party computation Son, YH; Han, K; Lee, YS; Yu, JH; Im, YH; Shin, SY
    View PubMed
  • MOL ONCOL 2021 10.1002/1878-0261.13141 The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial Triulzi, T; Bianchini, G; Di Cosimo, S; Pienkowski, T; Im, YH; Bianchi, GV; Galbardi, B; Dugo, M; De Cecco, L; Tseng, LM; Liu, MC; Bermejo, B; Semiglazov, V; Viale, G; de la Haba-Rodriguez, J; Oh, DY; Poirier, B; Valagussa, P; Gianni, L; Tagliabue, E
    View PubMed
  • CLIN CANCER RES 2021 10.1158/1078-0432.CCR-21-1560 Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors Takahashi, S; Karayama, M; Takahashi, M; Watanabe, J; Minami, H; Yamamoto, N; Kinoshita, I; Lin, CC; Im, YH; Achiwa, I; Kamiyama, E; Okuda, Y; Lee, C; Bang, YJ
    View PubMed
  • CANCERS 2021 10.3390/cancers13215260 Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy Jung, HH; Kim, JY; Cho, EY; Oh, JM; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • CANCERS 2021 10.3390/cancers13225835 Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach Kim, H; Kim, HJ; Kim, H; Kim, HR; Jo, H; Hong, J; Kim, R; Kim, JY; Ahn, JS; Im, YH; Lee, SK; Kim, H; Shin, SY; Park, YH
    View PubMed
  • FRONT ONCOL 2021 10.3389/fonc.2021.759150 Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer? Kim, JY; Oh, JM; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • SCI REP-UK 2021 10.1038/s41598-021-98408-8 Multimodal deep learning models for the prediction of pathologic response to neoadjuvant chemotherapy in breast cancer Joo, S; Ko, ES; Kwon, S; Jeon, E; Jung, H; Kim, JY; Chung, MJ; Im, YH
    View PubMed
  • CLIN BREAST CANCER 2021 10.1016/j.clbc.2020.12.013 Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype Kim, HK; Lee, HS; Heo, MH; Kim, JY; Ahn, JS; Im, YH; Lee, JI; Park, YH
    View PubMed
  • BREAST CANCER RES TR 2021 10.1007/s10549-021-06310-8 Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer Kim, JY; Jeon, E; Kwon, S; Jung, H; Joo, S; Park, Y; Lee, SK; Lee, JE; Nam, SJ; Cho, EY; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • FRONT ONCOL 2021 10.3389/fonc.2021.596364 Deep Learning-Based Prediction Model for Breast Cancer Recurrence Using Adjuvant Breast Cancer Cohort in Tertiary Cancer Center Registry Kim1, JY; Lee, YS; Yu, J; Park, Y; Lee, SK; Lee, M; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Kang, M; Im, YH
    View PubMed
  • J CLIN ONCOL 2021 10.1200/JCO.20.01204 Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up Piccart1, M; Procter, M; Fumagalli, D; de Azambuja, E; Clark, E; Ewer, MS; Restuccia, E; Jerusalem, G; Dent, S; Reaby, L; Bonnefoi, H; Krop, I; Liu, TW; Pienkowski, T; Toi, M; Wilcken, N; Andersson, M; Im, YH; Tseng, LM; Lueck, HJ; Colleoni, M; Monturus, E; Sicoe, M; Guillaume, S; Bines, J; Gelber, RD; Viale, G; Thomssen, C
    View PubMed
  • FRONT ONCOL 2021 10.3389/fonc.2021.653243 The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study Lee1, K; Sim, SH; Kang, EJ; Seo, JH; Chae, H; Lee, KS; Kim, JY; Ahn, JS; Im, YH; Park, S; Park, YH; Park, IH
    View PubMed
  • BREAST CANCER RES TREAT 2021 10.1007/s10549-021-06173-z Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES Im1, YH; Karabulut, B; Lee, KS; Park, BW; Adhav, A; Cinkir, HY; Abdel-Razeq, H; Chang, YC; Aksoy, S; Im, SA; Jeong, J; Chae, Y; Bowles, J; Slimane, K; Xue, HL; Kim, SB
    View PubMed
  • DIAGNOSTICS 2021 10.3390/diagnostics11020370 Local Laboratory Testing of Germline BRCA Mutations vs. Myriad: A Single-Institution Experience in Korea Hong1, J; Lee, J; Kwon, M; Kim, JY; Kim, JW; Ahn, JS; Im, YH; Park, YH
    View PubMed
  • ANN ONCOL 2021 10.1016/j.annonc.2020.10.596 Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial Dent1, S; Cortes, J; Im, YH; Dieras, V; Harbeck, N; Krop, IE; Wilson, TR; Cui, N; Schimmoller, F; Hsu, JY; He, J; De Laurentiis, M; Sousa, S; Drullinsky, P; Jacot, W
    View PubMed
  • ANN ONCOL 2020 10.1016/j.annonc.2020.08.2098 Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer final overall survival results from the EMBRACA trial Litton1, JK; Hurvitz, SA; Mina, LA; Rugo, HS; Lee, KH; Goncalves, A; Diab, S; Woodward, N; Goodwin, A; Yerushalmi, R; Roch, H; Im, YH; Eiermann, W; Quek, RGW; Usari, T; Lanzalone, S; Czibere, A; Blum, JL; Martin, M; Ettl, J
    View PubMed
  • BIOLOGY-BASEL 2020 10.3390/biology9110391 The Tumor-Fat Interface Volume of Breast Cancer on Pretreatment MRI Is Associated with a Pathologic Response to Neoadjuvant Chemotherapy Cho1, HH; Park, M; Park, H; Ko, ES; Hwang, NY; Im, YH; Ko, K; Sim, SH
    View PubMed
  • SCI REP-UK 2020 10.1038/s41598-020-75620-6 The incidence and clinical features of PEGylated filgrastim-induced acute aortitis in patients with breast cancer Lee1, SY; Kim, EK; Kim, JY; Park, TK; Choi, SH; Im, YH; Kim, MY; Park, YH; Kim, DK
    View PubMed
  • MOL CANCER RES 2020 10.1158/1541-7786.MCR-19-1108 Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer Park1, S; Lee, E; Park, S; Lee, S; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Kim, JY; Ahn, JS; Im, YH; Park, WY; Park, K; Park, YH
    View PubMed
  • SCI REP-UK 2020 10.1038/s41598-020-70584-z Cytokine profiling in serum-derived exosomes isolated by different methods Jung1, HH; Kim, JY; Lim, JE; Im, YH
    View PubMed
  • BREAST CANCER RES TR 2020 10.1007/s10549-020-05874-1 Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer Kim1, JY; Jung, HH; Sohn, I; Woo, SY; Cho, H; Cho, EY; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • THER ADV MED ONCOL 2020 10.1177/1758835920943065 Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy results from a phase III randomized clinical trial (MONALEESA-7) Harbeck1, N; Franke, F; Villanueva-Vazquez, R; Lu, YS; Tripathy, D; Chow, L; Babu, GK; Im, YH; Chandiwana, D; Gaur, A; Lanoue, B; Rodriguez-Lorenc, K; Bardia, A
    View PubMed
  • CANCERS 2020 10.3390/cancers12051306 Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience Hur1, JY; Kim, JY; Ahn, JS; Im, YH; Lee, J; Kwon, M; Park, YH
    View PubMed
  • LANCET ONCOL 2020 10.1016/S1470-2045(19)30863-0 Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study Swain1, SM; Miles, D; Kim, SB; Im, YH; Im, SA; Semiglazov, V; Ciruelos, E; Schneeweiss, A; Loi, S; Monturus, E; Clark, E; Knott, A; Restuccia, E; Benyunes, MC; Cortes, J
    View PubMed
  • SUPPORT CARE CANCER 2020 10.1007/s00520-019-04982-z Impact of a topical lotion, CG428, on permanent chemotherapy-induced alopecia in breast cancer survivors: a pilot randomized double-blind controlled clinical trial (VOLUME RCT) Kang1, D; Kim, IR; Park, YH; Im, YH; Zhao, D; Guallar, E; Ahn, JS; Cho, J
    View PubMed
  • LANCET ONCOL 2019 10.1016/S1470-2045(19)30565-0 Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial Park1, YH; Kim, TY; Kim, GM; Kang, SY; Park, IH; Kim, JH; Lee, KE; Ahn, HK; Lee, MH; Kim, HJ; Kim, HJ; Lee, JI; Koh, SJ; Kim, JY; Lee, KH; Sohn, J; Kim, SB; Ahn, JS; Im, YH; Jung, KH; Im, SA
    View PubMed
  • BRIT J CANCER 2019 10.1038/s41416-019-0618-z Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16) Sim1, SH; Park, IH; Jung, KH; Kim, SB; Ahn, JH; Lee, KH; Im, SA; Im, YH; Park, YH; Sohn, J; Kim, YJ; Lee, S; Kim, HJ; Chae, YS; Park, KH; Nam, BH; Lee, KS; Ro, J
    View PubMed
  • KOREAN JOURNAL OF INTERNAL MEDICINE 2019 10.3904/kjim.2017.226 Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy Heo1, MH; Kim, HK; Lee, H; Kim, JY; Ahn, JS; Im, YH; Park, YH
    View PubMed
  • CANCER 2019 10.1002/cncr.32392 Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE Perez1, EA; Barrios, C; Eiermann, W; Toi, M; Im, YH; Conte, P; Martin, M; Pienkowski, T; Pivot, XB; Burris, HA; Petersen, JA; De Haas, S; Hoersch, S; Patre, M; Ellis, PA
    View PubMed
  • CANCER COMMUN 2019 10.1186/s40880-019-0375-7 Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11) Kim1, JY; Park, S; Im, SA; Kim, SB; Sohn, J; Lee, KS; Chae, YS; Lee, KH; Kim, JH; Im, YH; Kim, TY; Lee, KH; Ahn, JH; Kim, GM; Park, IH; Lee, SJ; Han, HS; Kim, SH; Jung, KH; Park, YH
    View PubMed
  • BMC CANCER 2019 10.1186/s12885-019-5687-0 Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine +/- pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer Perez1, EA; de Haas, SL; Eiermann, W; Barrios, CH; Toi, M; Im, YH; Conte, PF; Martin, M; Pienkowski, T; Pivot, XB; Burris, HA; Stanzel, S; Patre, M; Ellis, PA
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.342 Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance Kim1, HK; Park, KH; Kim, Y; Park, SE; Lee, HS; Lim, SW; Cho, JH; Kim, JY; Lee, JE; Ahn, JS; Im, YH; Yu, JH; Park, YH
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.262 Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data Kim1, EK; Cho, J; Kim, JY; Chang, SA; Park, SJ; Choi, JO; Lee, SC; Ahn, JS; Park, SW; Im, YH; Jeon, ES; Park, YF
    View PubMed
  • ONCOLOGIST 2019 10.1634/theoncologist.2018-0184 Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study Kang1, D; Kim, IR; Choi, EK; Im, YH; Park, YH; Ahn, JS; Lee, JE; Nam, SJ; Lee, HK; Park, JH; Lee, DY; Lacouture, ME; Guallar, E; Cho, J
    View PubMed
  • SCI REP-UK 2019 10.1038/s41598-019-41098-0 Intratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicator Oh1, BY; Shin, HT; Yun, JW; Kim, KT; Kim, J; Bae, JS; Cho, YB; Lee, WY; Yun, SH; Park, YA; Park, YH; Im, YH; Lee, J; Joung, JG; Kim, HC; Park, WY
    View PubMed
  • ONCOL LETT 2019 10.3892/ol.2018.9754 Clinical features and prognosis of breast cancer with gastric metastasis Hong1, J; Kim, Y; Cho, J; Lim, SW; Park, SE; Kim, HK; Lee, H; Cho, SY; Kim, JY; Ahn, JS; Im, YH; Park, YH
    View PubMed
  • BREAST CANCER RES TR 2019 10.1007/s10549-018-4981-x A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients Hwang1, HW; Jung, H; Hyeon, J; Park, YH; Ahn, JS; Im, YH; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Lee, SK; Choi, M; Cho, SY; Cho, EY
    View PubMed
  • BMC CANCER 2019 10.1186/s12885-018-5258-9 Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea Kim1, HK; Lee, SH; Kim, YJ; Park, SE; Lee, HS; Lim, SW; Cho, JH; Kim, JY; Ahn, JS; Im, YH; Yu, JH; Park, YH
    View PubMed
  • HERED CANCER CLIN PR 2019 10.1186/s13053-018-0103-3 The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans Kim1, H; Choi, DH; Park, W; Im, YH; Ahn, JS; Park, YH; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Lee, SK; Jung, BY
    View PubMed
  • J BREAST CANC 2018 10.4048/jbc.2018.21.e48 PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis Seo1, Y; Park, YH; Ahn, JS; Im, YH; Nam, SJ; Cho, SY; Cho, EY
    View PubMed
  • INT J CANCER 2018 10.1002/ijc.31651 A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial Park1, YH; Lee, KH; Sohn, JH; Lee, KS; Jung, KH; Kim, JH; Lee, KH; Ahn, JS; Kim, TY; Kim, GM; Park, IH; Kim, SB; Kim, SH; Han, HS; Im, YH; Ahn, JH; Kim, JY; Kang, J; Im, SA
    View PubMed
  • EUR J CANCER 2018 10.1016/j.ejca.2018.08.004 Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study) Kim1, JY; Im, SA; Jung, KH; Ro, J; Sohn, J; Kim, JH; Park, YH; Kim, TY; Kim, SB; Lee, KS; Kim, GM; Kim, SH; Kim, S; Ahn, JS; Lee, KH; Ahn, JH; Park, IH; Im, YH
    View PubMed
  • BREAST CANCER RES TR 2018 10.1007/s10549-018-4858-z Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort Kim1, JY; Lim, JE; Jung, HH; Cho, SY; Cho, EY; Lee, SK; Yu, JH; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • CLIN BREAST CANCER 2018 10.1016/j.clbc.2018.04.010 Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment Cho1, WK; Choi, DH; Park, W; Cha, H; Nam, SJ; Kim, SW; Lee, JE; Yu, J; Im, YH; Ahn, JS; Park, YH; Kim, JY; Ahn, S
    View PubMed
  • ANN ONCOL 2018 10.1093/annonc/mdy257 Quality of life with talazoparib versus physician's choice of chemotherapy in patients wits advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA ease III trial Ettl1, J; Quek, RGW; Lee, KH; Rugo, HS; Hurvitz, S; Goncalves, A; Fehrenbacher, L; Yerushalmi, R; Mina, LA; Martin, M; Roche, H; Im, YH; Markova, D; Bhattacharyya, H; Hannah, AL; Eiermann, W; Blum, JL; Litton, JK
    View PubMed
  • NEW ENGL J MED 2018 10.1056/NEJMoa1802905 Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation Litton1, JK; Rugo, HS; Ettl, J; Hurvitz, SA; Goncalves, A; Lee, KH; Fehrenbacher, L; Yerushalmi, R; Mina, LA; Martin, M; Roche, H; Im, YH; Quek, RGW; Markova, D; Tudor, IC; Hannah, AL; Eiermann, W; Blum, JL
    View PubMed
  • LANCET ONCOL 2018 10.1016/S1470-2045(18)30292-4 Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial Tripathy1, D; Im, SA; Colleoni, M; Franke, F; Bardia, A; Harbeck, N; Hurvitz, SA; Chow, L; Sohn, J; Lee, KS; Campos-Gomez, S; Vazquez, RV; Jung, KH; Babu, KG; Wheatley-Price, P; De Laurentiis, M; Im, YH; Kuemmel, S; El-Saghir, N; Liu, MC; Carlson, G; Hughes, G; Diaz-Padilla, I; Germa, C; Hirawat, S; Lu, YS
    View PubMed
  • J BREAST CANC 2018 10.4048/jbc.2018.21.2.206 Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy? Cho1, WK; Park, W; Choi, DH; Cha, H; Nam, SJ; Kim, SW; Lee, JE; Yu, J; Im, YH; Ahn, JS; Park, YH; Kim, JY
    View PubMed
  • Oncoimmunology 2018 10.1080/2162402X.2018.1466768 Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer Park1, SE; Park, K; Lee, E; Kim, JY; Ahn, JS; Im, YH; Lee, C; Jung, H; Cho, SY; Park, WY; Cristescu, R; Park, YH
    View PubMed
  • BREAST CANCER RES TR 2018 10.1007/s10549-017-4628-3 Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06) Ponde1, N; Bradbury, I; Lambertini, M; Ewer, M; Campbell, C; Ameels, H; Zardavas, D; Di Cosimo, S; Baselga, J; Huober, J; Izquierdo, M; Fumagalli, D; Bozovic-Spasojevic, I; Maetens, M; Harbeck, N; Pusztai, L; Berghorn, M; Im, YH; Borrego, MR; Chen, DR; Rodeheffer, R; Piccart, M; Suter, T; de Azambuja, E
    View PubMed
  • NAT COMMUN 2018 10.1038/s41467-018-04129-4 Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures Kan1, ZY; Ding, Y; Kim, J; Jung, HH; Chung, W; Lal, S; Cho, S; Fernandez-Banet, J; Lee, SK; Kim, SW; Lee, JE; Choi, YL; Deng, S; Kim, JY; Ahn, JS; Sha, Y; Mu, XJ; Nam, JY; Im, YH; Lee, S; Park, WY; Nam, SJ; Park, YH
    View PubMed
  • ANN ONCOL 2018 10.1093/annonc/mdy034 Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+gastric cancer patients Kim1, ST; Banks, KC; Pectasides, F; Kim, SY; Kim, K; Lanman, RB; Talasaz, A; An, J; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, NKD; Park, W; Lee, H; Bass, AJ; Kim, K; Kang, WK; Lee, J
    View PubMed
  • ASIA-PAC J CLIN ONCO 2017 10.1111/ajco.12681 Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline Sohn1, BS; Kim, SB; Ahn, JH; Jung, KH; Kim, J; Lee, KS; Ro, J; Im, SA; Im, YH; Song, HS; Park, HS; Chung, HC
    View PubMed
  • EUR J CANCER 2017 10.1016/j.ejca.2017.10.002 Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer Park1, YH; Im, SA; Kim, SB; Sohn, JH; Lee, KS; Chae, YS; Lee, KH; Kim, JH; Im, YH; Kim, JY; Kim, TY; Lee, KH; Ahn, JH; Kim, GM; Park, IH; Lee, SJ; Han, HS; Kim, SH; Jung, KH
    View PubMed
  • ANN ONCOL 2017 10.1093/annonc/mdx406 Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial Miles1, D; Im, YH; Fung, A; Yoo, B; Knott, A; Heeson, S; Beattie, MS; Swain, SM
    View PubMed
  • NAT COMMUN 2017 10.1038/s41467-017-01470-y Prevalence and detection of low-allele-fraction variants in clinical cancer samples Shin1, HT; Choi, YL; Yun, JW; Kim, NKD; Kim, SY; Jeon, HJ; Nam, JY; Lee, C; Ryu, D; Kim, SC; Park, K; Lee, E; Bae, JS; Son, DS; Joung, JG; Lee, J; Kim, ST; Ahn, MJ; Lee, SH; Ahn, JS; Lee, WY; Oh, BY; Park, YH; Lee, JE; Lee, KH; Kim, HC; Kim, KM; Im, YH; Park, K; Park, PJ; Park, WY
    View PubMed
  • J BREAST CANC 2017 10.4048/jbc.2017.20.3.286 NanoString nCounter (R) Approach in Breast Cancer: A Comparative Analysis with Quantitative Real-Time Polymerase Chain Reaction, In Situ Hybridization, and Immunohistochemistry Hyeon1, J; Cho, SY; Hong, ME; Kang, SY; Doe, I; Im, YH; Cho, EY
    View PubMed
  • ASIA-PAC J CLIN ONCO 2017 10.1111/ajco.12652 Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy Kim1, H; Park, W; Huh, SJ; Choi, DH; Noh, JM; Im, YH; Ahn, JS; Park, YH; Nam, SJ; Kim, SW; Lee, JE; Cho, EY
    View PubMed
  • BREAST CANCER RES TR 2017 10.1007/s10549-017-4268-7 A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy Kim1, JY; Ok, ON; Seo, JJ; Lee, SH; Ahn, JS; Im, YH; Park, YH
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.17653 Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response Kim1, JY; Lee, E; Park, K; Park, WY; Jung, HH; Ahn, JS; Im, YH; Park, YH
    View PubMed
  • Cancer Res Treat. 2017 Apr;49(2):423-429. doi: 10.4143/crt.2016.191. Epub 2016 Aug 3. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results Park YH11, Kim TY2, Im YH1, Lee KS3, Park IH3, Sohn J4, Lee SH4, Im SA2, Kim JH5, Kim SH5, Lee SJ6, Koh SJ7, Lee KH8, Choi YJ9, Cho EK10, Lee S11, Kang SY12, Seo JH13, Kim SB14, Jung KH14.
    View PubMed
  • Oncotarget. 2017 Apr 25;8(17):27997-28007. doi: 10.18632/oncotarget.15881. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes Kim JY11, Lee E2, Park K2, Park WY2, Jung HH3, Ahn JS1, Im YH1,4, Park YH1,4,3.
    View PubMed
  • Support Care Cancer. 2017 Feb;25(2):505-511. doi: 10.1007/s00520-016-3429-2. Epub 2016 Oct 6. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer Park KH11, Lee S2, Park JH3, Kang SY4, Kim HY5, Park IH6, Park YH7, Im YH7, Lee HJ8, Park S9, Lee SI10, Jung KH11, Kim YS12, Seo JH13.
    View PubMed
  • Breast Cancer Res. 2017 Feb 9;19(1):16. doi: 10.1186/s13058-017-0806-9. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer Bianchini G11, Kiermaier A2, Bianchi GV3, Im YH4, Pienkowski T5, Liu MC6, Tseng LM7, Dowsett M8, Zabaglo L9, Kirk S10, Szado T11, Eng-Wong J11, Amler LC11, Valagussa P12, Gianni L13.
    View PubMed
  • J Clin Oncol. 2017 Jan 10;35(2):141-148. Epub 2016 Nov 7. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study Perez EA11, Barrios C1, Eiermann W1, Toi M1, Im YH1, Conte P1, Martin M1, Pienkowski T1, Pivot X1, Burris H 3rd1, Petersen JA1, Stanzel S1, Strasak A1, Patre M1, Ellis P1.
    View PubMed
  • Oncotarget. 2017 Jan 31;8(5):8693-8706. doi: 10.18632/oncotarget.14414. The effect of androgen receptor expression on clinical characterization of metastatic breast cancer Kim JY11, Park K2, Lee E2, Jung HH3, Ahn JS1, Im YH1,4, Park WY2,5, Park YH1,4,3.
    View PubMed
  • Breast Cancer Res Treat. 2016 Dec;160(3):475-489. doi: 10.1007/s10549-016-4008-4. Epub 2016 Oct 11. Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems Choi M11, Park YH2, Ahn JS2, Im YH2, Nam SJ3, Cho SY4, Cho EY5.
    View PubMed
  • Cancer Res Treat. 2016 Oct;48(4):1382-1388. Epub 2016 Mar 11. Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea Kim HK11, Ham JS1, Byeon S1, Yoo KH1, Jung KS1, Song HN1, Cho J1, Lee JY1, Lim SH1, Kim HS1, Kim JY1, Lee JE2, Kim SW2, Nam SJ2, Lee SK2, Bae SY2, Ahn JS1, Im YH1, Park YH1.
    View PubMed
  • PLoS One. 2016 Oct 31;11(10):e0165814. doi: 10.1371/journal.pone.0165814. eCollection 2016. Body Mass Index with Tumor F-18-FDG Uptake Improves Risk Stratification in Patients with Breast Cancer Hyun SH11, Ahn HK2, Lee JH1, Choi JY1, Kim BT1, Park YH3, Im YH3, Lee JE4, Nam SJ4, Lee KH1.
    View PubMed
  • Cancer Res Treat. 2016 Oct;48(4):1373-1381. Epub 2016 Mar 23. Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study Kim SH11, Jung KH2, Kim TY3, Im SA3, Choi IS4, Chae YS5, Baek SK6, Kang SY7, Park S8, Park IH9, Lee KS9, Choi YJ10, Lee S11, Sohn JH11, Park YH12, Im YH12, Ahn JH2, Kim SB2, Kim JH1.
    View PubMed
  • Cancer Res Treat. 2016 Oct;48(4):1338-1350. Epub 2016 Feb 18. Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer Kim JY11, Park K2, Jung HH3, Lee E2, Cho EY4, Lee KH5, Bae SY6, Lee SK6, Kim SW6, Lee JE6, Nam SJ6, Ahn JS1, Im YH1,3, Park YH1,3.
    View PubMed
  • Sci Rep. 2016 Sep 8;6:33035. doi: 10.1038/srep33035. Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency Jung HH11, Lee SH2, Kim JY2, Ahn JS2, Park YH1,2,3, Im YH2,3.
    View PubMed
  • Medicine (Baltimore). 2016 Aug;95(32):e4266. doi: 10.1097/MD.0000000000004266. Relation between primary tumor FDG avidity and site of first distant metastasis in patients with breast cancer Lim CH11, Moon SH, Cho YS, Im YH, Choe YS, Kim BT, Lee KH.
    View PubMed
  • SCIENTIFIC REPORTS, AUG 22 2016, 6, DOI: 10.1038/srep31804 The relationship between nuclear factor (NF)-kappa B family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment Kim JY1, Jung HH, Ahn S, Bae S, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH
    View PubMed
  • Lancet Oncol. 2016 Jun;17(6):791-800. doi: 10.1016/S1470-2045(16)00163-7. Epub 2016 May 11. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial Gianni L11, Pienkowski T2, Im YH3, Tseng LM4, Liu MC5, Lluch A6, Starosławska E7, de la Haba-Rodriguez J8, Im SA9, Pedrini JL10, Poirier B11, Morandi P12, Semiglazov V13, Srimuninnimit V14, Bianchi GV15, Magazzu D16, McNally V17, Douthwaite H17, Ross G18, Valagussa P16.
    View PubMed
  • J Breast Cancer. 2016 Jun;19(2):169-75. doi: 10.4048/jbc.2016.19.2.169. Epub 2016 Jun 24. Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes Kim SW11, Choi DH2, Huh SJ2, Park W2, Nam SJ3, Kim SW3, Lee JE3, Im YH4, Ahn JS4, Park YH4.
    View PubMed
  • Clin Breast Cancer. 2016 Jun;16(3):e15-21. doi: 10.1016/j.clbc.2015.11.008. Epub 2015 Dec 11. Limited Supraclavicular Radiation Field in Breast Cancer With >= 10 Positive Axillary Lymph Nodes Yu JI11, Park W2, Choi DH1, Huh SJ1, Nam SJ3, Kim SW3, Lee JE3, Kil WH3, Im YH4, Ahn JS4, Park YH4, Cho EY5.
    View PubMed
  • Sci Rep. 2016 Jun 24;6:28623. doi: 10.1038/srep28623. Gene Expression Profiling of Breast Cancer Brain Metastasis Lee JY11, Park K2, Lee E2, Ahn T2, Jung HH3, Lim SH1, Hong M4, Do IG4, Cho EY4, Kim DH5, Kim JY1, Ahn JS1, Im YH1,2, Park YH1,3.
    View PubMed
  • Cancer Res Treat. 2016 Apr;48(2):499-507. doi: 10.4143/crt.2015.089. Epub 2015 Jul 14. Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer Yoo C11, Kim SB1, Ro J2, Im SA3, Im YH4, Kim JH5, Ahn JH1, Jung KH1, Song HS6, Kang SY7, Park HS8, Chung HC9.
    View PubMed
  • J Clin Oncol. 2016 Apr 1;34(10):1034-42. doi: 10.1200/JCO.2015.62.1797. Epub 2015 Nov 23. Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial Piccart-Gebhart M11, Holmes E1, Baselga J1, de Azambuja E1, Dueck AC1, Viale G1, Zujewski JA1, Goldhirsch A1, Armour A1, Pritchard KI1, McCullough AE1, Dolci S1, McFadden E1, Holmes AP1, Tonghua L1, Eidtmann H1, Dinh P1, Di Cosimo S1, Harbeck N1, Tjulandin S1, Im YH1, Huang CS1, Dieras V1, Hillman DW1, Wolff AC1, Jackisch C1, Lang I1, Untch M1, Smith I1, Boyle F1, Xu B1, Gomez H1, Suter T1, Gelber RD1, Perez EA1.
    View PubMed
  • Lancet Oncol. 2016 Mar;17(3):357-66. doi: 10.1016/S1470-2045(15)00540-9. Epub 2016 Jan 26. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial Harbeck N11, Huang CS2, Hurvitz S3, Yeh DC4, Shao Z5, Im SA6, Jung KH7, Shen K8, Ro J9, Jassem J10, Zhang Q11, Im YH12, Wojtukiewicz M13, Sun Q14, Chen SC15, Goeldner RG16, Uttenreuther-Fischer M16, Xu B17, Piccart-Gebhart M18; LUX-Breast 1 study group.
    View PubMed
  • PLoS One. 2016 Feb 22;11(2):e0149432. doi: 10.1371/journal.pone.0149432. eCollection 2016. The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC) Lee JY11, Lim SH1, Lee MY1, Kim HS1, Ahn JS1, Im YH1, Park YH1.
    View PubMed
  • BMC Cancer. 2016 Feb 22;16:138. doi: 10.1186/s12885-016-2195-3. Prognostic value of ERBB4 expression in patients with triple negative breast cancer Kim JY11, Jung HH2, Do IG3, Bae S4, Lee SK5, Kim SW6, Lee JE7, Nam SJ8, Ahn JS9, Park YH10,11, Im YH12,13.
    View PubMed
  • Clin Breast Cancer. 2015 Dec;15(6):512-8. doi: 10.1016/j.clbc.2015.06.004. Epub 2015 Jun 18. Clinical Outcomes and Prognostic Factors of Pathologic N3 Breast Cancer Treated With Modern Standard Treatments Yu JI11, Park W2, Choi DH1, Huh SJ1, Nam SJ3, Kim SW3, Lee JE3, Kil WH3, Im YH4, Ahn JS4, Park YH4, Cho EY5.
    View PubMed
  • Ann Oncol. 2015 Dec;26(12):2429-36. doi: 10.1093/annonc/mdv395. Epub 2015 Sep 19. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial Bianchini G11, Pusztai L2, Pienkowski T3, Im YH4, Bianchi GV5, Tseng LM6, Liu MC7, Lluch A8, Galeota E1, Magazzu D9, de la Haba-Rodriguez J10, Oh DY11, Poirier B12, Pedrini JL13, Semiglazov V14, Valagussa P9, Gianni L15.
    View PubMed
  • Oncotarget. 2015 Dec 22;6(41):43731-42. doi: 10.18632/oncotarget.6192. Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer Lee JY11, Park K2, Lim SH1, Kim HS1, Yoo KH1, Jung KS1, Song HN1, Hong M3, Do IG3, Ahn T2, Lee SK4, Bae SY4, Kim SW4, Lee JE4, Nam SJ4, Kim DH5, Jung HH6, Kim JY1, Ahn JS1, Im YH1, Park YH1.
    View PubMed
  • Ann Surg Oncol. 2015 Oct;22(11):3481-8. doi: 10.1245/s10434-015-4399-1. Epub 2015 Feb 5. The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women Kim J11, Han W2, Jung SY3, Park YH4, Moon HG5, Ahn SK6, Lee JW7, Kim MK5, Kim JJ5, Lee ES5, You TK1, Kang HS3, Lee ES3, Ro J3, Lee JE4, Nam SJ4, Yim YH4, Park IA5, Noh DY5.
    View PubMed
  • Cancer Res Treat. 2015 Oct;47(4):765-73. doi: 10.4143/crt.2014.168. Epub 2015 Jan 13. Impact on Survival of Regular Postoperative Surveillance for Patients with Early Breast Cancer Lee JY11, Lim SH1, Lee MY1, Kim H1, Kim M1, Kim S1, Jung HA1, Sohn I2, Gil WH3, Lee JE3, Kim SW3, Nam SJ3, Ahn JS1, Im YH1, Park YH1.
    View PubMed
  • BMC Cancer. 2015 Oct 14;15:693. doi: 10.1186/s12885-015-1716-9. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study Lee SJ11, Kim S2, Kim M3, Lee J4, Park YH5, Im YH6, Park SH7.
    View PubMed
  • Oncotarget. 2015 Oct 13;6(31):32027-38. doi: 10.18632/oncotarget.5184. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer Park YH11,2, Shin HT3, Jung HH2, Choi YL3, Ahn T3, Park K3, Lee A4, Do IG5, Kim JY1,2, Ahn JS1, Park WY3, Im YH1,2.
    View PubMed
  • Oncotarget. 2015 Sep 15;6(27):24499-510. Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay Park K11, Choi MK2, Jung HH3, Do IG4, Lee KH5, Ahn T1, Kil WH6, Kim SW6, Lee JE6, Nam SJ6, Kim DH7, Ahn JS2, Im YH2,3, Park YH2,3.
    View PubMed
  • Cancer?Chemother Pharmacol.?2014 Sep;74(3):521-9. doi: 10.1007/s00280-014-2542-5. Epub 2014 Jul 22. Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer Choi MK11,?Park YH,?Kil WH,?Lee JE,?Nam SJ,?Ahn JS,?Im YH.
    View PubMed
  • Oncology.?2014;86(5-6):279-88. doi: 10.1159/000362281. Epub 2014 Jun 4. Validation and Comparison of CS-IHC4 Scores with a Nomogram to Predict Recurrence in Hormone Receptor-Positive Breast Cancers Park YH11,?Im SA,?Cho EY,?Ahn JH,?Woo SY,?Kim S,?Keam B,?Lee JE,?Han W,?Nam SJ,?Park IA,?Noh DY,?Yang JH,?Ahn JS,?Im YH.
    View PubMed
  • Cancer Res Treat. 2014 Apr;46(2):200-3. doi: 10.4143/crt.2014.46.2.200. Epub 2014 Apr 22. Intra-tumoral Metastatic Double Primary Carcinoma: Synchronous Metastatic Tumor in Lung from Breast and Thyroid Carcinoma Park LC11, Jeong JY2, Ji JH3, Park S3, Ahn JS3, Im YH3, Park YH3.
    View PubMed
  • Eur J Cancer. 2014 Mar;50(4):698-705. doi: 10.1016/j.ejca.2013.11.028. Epub 2013 Dec 18. Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy Lee SY11, Im SA2, Park YH3, Woo SY4, Kim S4, Choi MK5, Chang W5, Ahn JS5, Im YH5.
    View PubMed
  • Ann Oncol. 2014 Feb;25(2):346-51. doi: 10.1093/annonc/mdt476. Epub 2013 Dec 29. Development and validation of Chemotherapy-induced Alopecia Distress Scale (CADS) for breast cancer patients Cho J11, Choi EK, Kim IR, Im YH, Park YH, Lee S, Lee JE, Yang JH, Nam SJ.
    View PubMed
  • Br J?Cancer.?2014 Jan 21;110(2):384-91. doi: 10.1038/bjc.2013.757. Epub 2013 Dec 17. Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment Park YH11,?Jung HA1,?Choi MK1,?Chang W1,?Choi YL2,?Do IG2,?Ahn JS1,?Im YH1.
    View PubMed
  • Biochem Biophys Res Commun.?2013 Sep 20;439(2):275-9. doi: 10.1016/j.bbrc.2013.08.043. Epub 2013 Aug 21. Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway Park YH11,?Jung HH,?Ahn JS,?Im YH.
    View PubMed
  • Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02
    View PubMed
  • Neuro Oncol.?2012 Aug;14(8):1105-13. doi: 10.1093/neuonc/nos137. Epub 2012 Jun 11. Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogram Ahn HK11,?Lee S,?Park YH,?Sohn JH,?Jo JC,?Ahn JH,?Jung KH,?Park S,?Cho EY,?Lee JI,?Park W,?Choi DH,?Huh SJ,?Ahn JS,?Kim SB,?Im YH.
    View PubMed
  • Breast?Cancer Res Treat.?2012 May;133(1):247-55. doi: 10.1007/s10549-012-1956-1. Epub 2012 Jan 21. Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: Is there a subpopulation that might have benefit from adjuvant chemotherapy Park YH11,?Im SA,?Cho EY,?Choi YL,?Lee JE,?Nam SJ,?Yang JH,?Ahn JS,?Im YH.
    View PubMed
  • Implications of Different CA 15-3 Levels according to Breast Cancer Subtype at Initial Diagnosis of Recurrent or Metastatic Breast Cancer
    View PubMed
  • Breast?Cancer?Res Treat.?2011 Oct;129(3):809-17. doi: 10.1007/s10549-011-1682-0. Epub 2011 Jul 23. Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations Lee S11,?Ahn HK,?Park YH,?Nam do H,?Lee JI,?Park W,?Choi DH,?Huh SJ,?Park KT,?Ahn JS,?Im YH.
    View PubMed
  • Cancer?Chemother Pharmacol.?2011 Sep;68(3):753-61. doi: 10.1007/s00280-010-1548-x. Epub 2010 Dec 18. Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC) Cho EY11,?Chang MH,?Choi YL,?Lee JE,?Nam SJ,?Yang JH,?Park YH,?Ahn JS,?Im YH.
    View PubMed
  • Oncology.?2011;81(1):55-62. doi: 10.1159/000331417. Epub 2011 Sep 16. Patterns of Skin and Soft Tissue Metastases from Breast Cancer according to Subtypes: Relationship between EGFR Overexpression and Skin Manifestations Kong JH11,?Park YH,?Kim JA,?Kim JH,?Yun J,?Sun JM,?Won YW,?Lee S,?Kim ST,?Cho EY,?Ahn JS,?Im YH.
    View PubMed
  • Cancer Chemother Pharmacol. 2011 Sep;68(3):743-51. doi: 10.1007/s00280-010-1545-0. Epub 2010 Dec 18. Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer Lee SJ11, Choi YL, Park YH, Kim ST, Cho EY, Ahn JS, Im YH.
    View PubMed
  • Ann Oncol.?2011 Jul;22(7):1554-60. doi: 10.1093/annonc/mdq617. Epub 2011 Jan 17. Clinical relevance of TNM staging system according to breast cancer subtypes Park YH11,?Lee SJ,?Cho EY,?Choi YL,?Lee JE,?Nam SJ,?Yang JH,?Shin JH,?Ko EY,?Han BK,?Ahn JS,?Im YH.
    View PubMed
  • Cancer?Res Treat.?2011 Jun;43(2):89-95. doi: 10.4143/crt.2011.43.2.89. Epub 2011 Jun 30. Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer Lee SJ11,?Park S,?Ahn HK,?Yi JH,?Cho EY,?Sun JM,?Lee JE,?Nam SJ,?Yang JH,?Park YH,?Ahn JS,?Im YH.
    View PubMed
  • Biochem Biophys Res Commun.?2011 Apr 22;407(4):680-6. doi: 10.1016/j.bbrc.2011.03.075. Epub 2011 Apr 2. ERK/MAPK pathways play critical roles in EGFR ligands-induced MMP1 expression Park S11,?Jung HH,?Park YH,?Ahn JS,?Im YH.
    View PubMed
  • Br J?Cancer.?2011 Feb 15;104(4):559-63. doi: 10.1038/bjc.2011.4. Epub 2011 Feb 1. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy Yun J11,?Kim KH,?Kang ES,?Gwak GY,?Choi MS,?Lee JE,?Nam SJ,?Yang JH,?Park YH,?Ahn JS,?Im YH.
    View PubMed
  • CA 15-3 kinetics: clinical implication of CA 15-3 surge in metastatic breast cancer
  • Med Oncol.?2010 Dec;27(4):1234-8. doi: 10.1007/s12032-009-9364-z. Epub 2009 Nov 19. Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA) Choi MK11,?Park YH,?Hong JY,?Park HC,?Ahn YC,?Kim K,?Shim YM,?Kang WK,?Park K,?Im YH.
    View PubMed
  • Br J Cancer.?2010 Sep 7;103(6):845-51. doi: 10.1038/sj.bjc.6605831. Epub 2010 Aug 10. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma Lee S11,?Park YH,?Kim KH,?Cho EY,?Ahn YC,?Kim K,?Shim YM,?Ahn JS,?Park K,?Im YH.
    View PubMed
  • Cancer?Chemother Pharmacol.?2010 Aug;66(3):507-16. doi: 10.1007/s00280-009-1190-7. Epub 2009 Dec 3. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status Park YH11,?Lee S,?Cho EY,?Choi YL,?Lee JE,?Nam SJ,?Yang JH,?Ahn JS,?Im YH.
    View PubMed
  • Mol Cancer Res.?2010 Jul;8(7):1037-47. doi: 10.1158/1541-7786.MCR-09-0469. Epub 2010 Jun 15. Matrix Metalloproteinase-1 Expression Can Be Upregulated through Mitogen-Activated Protein Kinase Pathway under the Influence of Human Epidermal Growth Factor Receptor 2 Synergized with Estrogen Receptor Jung HH11,?Park YH,?Jun HJ,?Kong J,?Kim JH,?Kim JA,?Yun J,?Sun JM,?Won YW,?Lee S,?Kim ST,?Ahn JS,?Im YH.
    View PubMed
  • Breast?Cancer?Res Treat.?2010 Feb;119(3):653-61. doi: 10.1007/s10549-009-0665-x. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (<= 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment Park YH11,?Kim ST,?Cho EY,?Choi YL,?Ok ON,?Baek HJ,?Lee JE,?Nam SJ,?Yang JH,?Park W,?Choi DH,?Huh SJ,?Ahn JS,?Im YH.
    View PubMed
  • Breast Cancer?Res Treat.?2009 Nov;118(1):89-97. doi: 10.1007/s10549-009-0377-2. Epub 2009 Mar 26. Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer Kim HS11,?Park YH,?Park MJ,?Chang MH,?Jun HJ,?Kim KH,?Ahn JS,?Kang WK,?Park K,?Im YH.
    View PubMed
  • Int J?Cancer.?2009 Mar 15;124(6):1457-62. doi: 10.1002/ijc.24090. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy Uhm JE11,?Park YH,?Yi SY,?Cho EY,?Choi YL,?Lee SJ,?Park MJ,?Lee SH,?Jun HJ,?Ahn JS,?Kang WK,?Park K,?Im YH.
    View PubMed
  • Br J?Cancer.?2009 Mar 24;100(6):894-900. doi: 10.1038/sj.bjc.6604941. Epub 2009 Feb 24. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients Park YH11,?Park MJ,?Ji SH,?Yi SY,?Lim DH,?Nam DH,?Lee JI,?Park W,?Choi DH,?Huh SJ,?Ahn JS,?Kang WK,?Park K,?Im YH.
    View PubMed
  • Cancer?Chemother Pharmacol.?2009 Mar;63(4):627-33. doi: 10.1007/s00280-008-0779-6. Epub 2008 Jun 14. Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes Park BB11,?Uhm JE,?Cho EY,?Choi YL,?Ji SH,?Nam do H,?Il Lee J,?Park W,?Huh SJ,?Park YH,?Ahn JS,?Im YH.
    View PubMed
  • Biochem Biophys Res Commun.?2008 Dec 12;377(2):389-94. doi: 10.1016/j.bbrc.2008.09.135. Epub 2008 Oct 11. Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells Park YH11,?Jung HH,?Ahn JS,?Im YH.
    View PubMed
  • Invest New Drugs.?2008 Aug;26(4):387-92. doi: 10.1007/s10637-008-9126-3. Epub 2008 Mar 27. Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma Park BB11,?Im YH,?Hwang IG,?Lee SC,?Ahn JS,?Ahn MJ,?Lim HY,?Kang WK,?Park K.
    View PubMed
  • Cancer Chemother Pharmacol.?2008 Jun;62(1):77-84. Epub 2007 Aug 31. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma Lee J11,?Im YH,?Cho EY,?Hong YS,?Lee HR,?Kim HS,?Kim MJ,?Kim K,?Kang WK,?Park K,?Shim YM.
    View PubMed
  • Cancer?Chemother Pharmacol.?2008 Apr;61(4):569-77. Epub 2007 May 17. Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer Lee J11,?Im YH,?Lee SH,?Cho EY,?Choi YL,?Ko YH,?Kim JH,?Nam SJ,?Kim HJ,?Ahn JS,?Park YS,?Lim HY,?Han BK,?Yang JH.
    View PubMed
  • Acta Oncol. 2007;46(7):996-1003. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: Relation to response patterns on MRI Kim HJ11, Im YH, Han BK, Choi N, Lee J, Kim JH, Choi YL, Ahn JS, Nam SJ, Park YS, Choe YH, Ko YH, Yang JH.
    View PubMed
  • Oncol Rep.?2006 Jun;15(6):1541-9. Interferon-alpha resistance can be reversed by inhibition of IFN-alpha-induced COX-2 expression potentially via STAT1 activation in A549 cells Lee J11,?Jung HH,?Im YH,?Kim JH,?Park JO,?Kim K,?Kim WS,?Ahn JS,?Jung CW,?Park YS,?Kang WK,?Park K.
    View PubMed
  • Ann Thorac Surg.?2005 Oct;80(4):1170-5. Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma Lee J11,?Lee KE,?Im YH,?Kang WK,?Park K,?Kim K,?Shim YM.
    View PubMed
  • Biochem Biophys Res Commun.?2005 Aug 26;334(2):313-8. Curcumin inhibits interferon-alpha induced NF-kappa B and COX-2 in human A549 non-small cell lung cancer cells Lee J11,?Im YH,?Jung HH,?Kim JH,?Park JO,?Kim K,?Kim WS,?Ahn JS,?Jung CW,?Park YS,?Kang WK,?Park K.
    View PubMed
  • FEBS Lett.?2005 Jul 18;579(18):3941-6. STAT1 and Nmi are downstream targets of Ets-1 transcription factor in MCF-7 human breast cancer cell Jung HH11,?Lee J,?Kim JH,?Ryu KJ,?Kang SA,?Park C,?Sung K,?Nam DH,?Kang WK,?Park K,?Im YH.
    View PubMed
  • Med Oncol.?2004;21(3):223-31. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer Lee SH11,?Lee J,?Park J,?Park SH,?Lee KE,?Lee SI,?Nam E,?Park JO,?Kim K,?Jung CW,?Park YS,?Yoon SS,?Kang WK,?Lee MH,?Park K,?Im YH.
    View PubMed